Model Informed Precision Dosing of Tacrolimus in Children Following Heart Transplant
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70122 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Jadon S Wagstaff und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Tacrolimus, Heart Transplantation, Immunosuppressive Agents, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Tacrolimus is a first‐line immunosuppressant used after solid organ transplantation that suffers from extensive intra‐ and inter‐patient variability and a narrow therapeutic window. Its critical role in a fragile population, coupled with the difficulties identifying and maintaining an appropriate dose within a given patient, make it an ideal candidate for population pharmacokinetic (popPK)‐guided individualized dosing approaches (i.e., model informed precision dosing, MIPD). We previously published a tacrolimus popPK model in pediatric heart transplant recipients that showed promise in its ability to predict future concentrations within an individual. Using that model, we developed a Bayesian forecasting decision support tool (DST) clinical use to more rapidly attain appropriate tacrolimus dosing in this population. After rigorous in silico testing of the DST's mathematical fidelity to the popPK model, we implemented the DST within a clinical trial (NCT04380311). Fifteen children between 6 months and 17 years of age had their tacrolimus doses guided by the DST to determine the time to stable therapeutic tacrolimus dosing (defined by three consecutive concentrations within the targeted therapeutic range). DST‐guided dosing achieved stable tacrolimus dosing ∼3 days faster (6.9 days, P = .03) as compared to a historical cohort (9.8 days). This was despite the poor performance of the DST in two children treated with continuous renal replacement therapy. These results demonstrate the clinical utility and benefit of the described DST, which is the first targeted to the pediatric heart transplant population. Rapid attainment of stable therapeutic tacrolimus dosing has benefits for the patient, clinician, and the healthcare system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- Primary Children's Medical Center, Intermountain Healthcare, Salt Lake City, Utah, USA.
- Division of Cardiology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.
- Center for Human Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.
ORCID-Profile: Jadon S Wagstaff, Joseph E Rower
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Wagstaff, J. S., Kumar, S. S., Molina, K. M., & Rower, J. E. (2026). Model Informed Precision Dosing of Tacrolimus in Children Following Heart Transplant. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70122
Vancouver
Wagstaff JS, Kumar SS, Molina KM, Rower JE. Model Informed Precision Dosing of Tacrolimus in Children Following Heart Transplant. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70122
BibTeX
@article{Wagstaff2026,
author = {Wagstaff, Jadon S and Kumar, Shaun S and Molina, Kimberly M and Rower, Joseph E},
title = {Model Informed Precision Dosing of Tacrolimus in Children Following Heart Transplant},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70122}
}
EUVIMED